237 related articles for article (PubMed ID: 24658031)
1. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
[TBL] [Abstract][Full Text] [Related]
2. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
6. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
7. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Nishimura Y; Bereczky B; Ono M
Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
10. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
11. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Nishimura Y; Yoshioka K; Bereczky B; Itoh K
Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
[TBL] [Abstract][Full Text] [Related]
12. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
[TBL] [Abstract][Full Text] [Related]
13. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
15. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
16. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
17. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
Cui G; Cui M; Li Y; Liang Y; Li W; Guo H; Zhao S
Med Oncol; 2015 Apr; 32(4):124. PubMed ID: 25788032
[TBL] [Abstract][Full Text] [Related]
19. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
